Money is not the issue. They have loads of money for a startup, and they're moving very fast. The problem is regulators. They know very well they are sitting on a gold mine. Most biotech startups are lucky to be able to do a single trial. HMI is already preparing for clinical trials in fibroid duct disease in addition to the two other indications they have going, and they're doing preclinical work on rheumatioid arthiritis and other diseases.Was just remarking the fact that there seems to be enough demand for a very profitable venture, I would of course want to pay the fairest price.
If to speed up the process they can release some pre-round that is more expensive to raise money, then be it.